Table 2

 Patient and disease characteristics for those with complete remission and those with no or partial remission on induction treatment with mycophenolate mofetil and prednisolone

CR (n = 25)NR and PR (n = 7)
ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CR, complete remission; CRP, C reactive protein; MPA, microscopic polyangiitis; MPO, myeloperoxidase; NR, no remission; PR, partial remission; PR3, proteinase 3; WG Wegener’s granulomatosis.
Values are represented as median (range) or n (%).
*One patient with newly diagnosed disease being treated with mycophenolate mofetil was excluded from this analysis.
Age (years)51 (23–74)55 (38–81)
ANCA PR3/MPO/negative20/3/27/0/0
Duration of disease (years)6.0 (0–21.6)2.9 (0.3–11.1)
Previous relapses4 (0–14)3 (1–4)
BVAS13 (5–29)15 (6–27)
CRP (normal <10 mg/l)39 (1–311)35 (6–361)
Creatinine (normal <125 μmol/l)110 (73–500)99 (88–542)
Relapses13 (52)6 (100)
Time to relapse (months)14 (3–58)6 (2–10)
Interval between previous and current relapse (months)19 (4–134)11 (3–18)
Previous episode successfully treated with cyclophosphamide*21 (84)3 (50)